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Abstract
Introduction: Statins belong to the most commonly used medicines worldwide. They affect cholesterol synthesis and thus they may sup-
press steroidogenesis. Our aim was to evaluate whether the use of statins is associated with the concentration of sex hormones. 
Material and methods/Results: In a population sample of men (n = 237) we found that subjects receiving statins had significantly lower 
concentrations of: total testosterone (14.9 vs. 16.35 nmol/L, p = 0.008 after correction for body mass), free testosterone (32 vs. 39 pmol/L, 
p = 0.004), calculated free testosterone (0.32 vs. 0.36 nmol/L, p < 0.001) and bioavailable testosterone (6.10 vs. 7.56 nmol/L, p < 0.001) than 
age-matched controls. 
Conclusions: We conclude that the use of statins may have an impact on the diagnosis of age-related testosterone deficiency in men. 
(Endokrynol Pol 2014; 65 (6): 464–468)
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Streszczenie
Wstęp: Statyny są jednymi z najpowszechniej stosowanych leków na świecie. Środki te wpływają na syntezę cholesterolu i pośrednio 
mogą oddziaływać na steroidogenezę. Celem badań była weryfikacja hipotezy o występowaniu związku między stosowaniem statyn 
a stężeniami hormonów płciowych. 
Materiał i metody/Wyniki: W grupie mieszkańców Dolnego Śląska (n = 237) stwierdzono, że w porównaniu z dobranymi pod względem 
wieku mężczyznami z grupy kontrolnej, mężczyźni leczeni statynami mieli znacząco niższe stężenia: testosteronu całkowitego (14,9 vs. 
16,35 nmol/l, p = 0.008 po korekcji na masę ciała), wolnego testosteronu (32 vs. 39 pmol/l, p = 0.004), kalkulowanego wolnego testosteronu 
(0,32 vs. 0,36 nmol/l, p < 0.001) i testosteronu biodostępnego (6,10 vs. 7,56 nmol/l, p < 0.001). 
Wnioski: Uzyskane wyniki sugerują, że stosowanie statyn może mieć wpływ na diagnozowanie niedomogi androgennej u starzejących 
się mężczyzn. (Endokrynol Pol 2014; 65 (6): 464–468)
Słowa kluczowe: inhibitory hydroksymetylglutarylo-CoA reduktazy; hormony steroidowe; testosteron; mężczyźni
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Introduction 
Statins — thanks to their demonstrated efficacy in the 
primary and secondary prevention of cardiovascular 
disease — are commonly used medicines. It is estimated 
that between 7% and 20% of adult and elderly patients 
are currently taking statins.
In view of the growing epidemiological significance 
of cardiovascular disease and diabetes mellitus in de-
veloped countries, statin use is expected to increase. 
A thorough analysis is therefore warranted that would 
address all the health aspects of their chronic use and 
the incidence of their adverse effects.
Statins exert pleiotropic effects which ultimately 
result in reduced atherosclerosis-related morbidity and 
reduced mortality. They exert hypolipidaemic effects 
by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme 
A reductase, a liver enzyme that regulates endogenous 
cholesterol synthesis. 
Cholesterol is an essential substrate for the synthesis 
of steroid hormones. It is delivered to the gonads and 
the adrenal glands mainly by low-density lipoproteins 
(LDLs) with only small amounts of it being synthesised 
directly in the cells of these organs [1]. 
So it is reasonable to hypothesise that the use of 
statins may suppress steroidogenesis [2–6]. A certain 
role may also be played by other mechanisms of action 
identified in the case of statins, such as the inhibition 
of 17-hydroxysteroid dehydrogenase activity (simvas-
tatin) [1, 7]. 
The extensively investigated age-related decline in 
testosterone levels is related to the so-called late-onset 
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free testosterone (FT), bioavailable testosterone (bioT), 
calculated free testosterone (cFT) and dehydroepian-
drosterone sulfate (DHEA-S), luteinising hormone (LH), 
follicle-stimulating hormone (FSH), oestradiol (E2) and 
sex hormone binding globulin (SHBG).
SHBG, LH and FSH were measured by IRMA (Im-
munotech, Prague, Czech Republic), and T, FT and 
DHEA-S were measured by RIA (DPC, Los Angeles, CA, 
USA). BioT and cFT were calculated using the calculator 
found on the International Society for the Study of the 
Ageing Male website using the values of T and SHBG 
concentrations and the standard albumin concentration 
(4.3 g/dL). The within- and between-series coefficients 
of variability were, respectively: 6.5% and 6.7% for T, 
6.2% and 8.5% for FT, 4.4% and 7.7% for DHEA-S, 3.8% 
and 7.0% for SHBG, 1.8% and 3.1% for LH, and 8.1% 
and 5.4% for FSH.
Statistical calculations were performed using Sta-
tistica 10.0 (StatSoft). The distribution of variables was 
assessed using the Shapiro-Wilk test for normality. 
The hormonal parameters between the groups were 
compared using the analysis of variance and covariance 
(body mass as a confounder). The statistical significance 
was determined at p < 0.05.
Results
There were no significant differences of age between 
Group S and Group NS. 
Treatment with statins was associated with reduced 
FT, cFT and bioT and increased SHBG. After adjusting 
for body mass, men using statins showed lower T and 
T/E2 ratio.
There were no significant differences between the 
groups in the levels of the other hormonal parameters, 
i.e. LH, FSH, E2, and DHEA-S (Table I).
Discussion
Our study showed that treatment with statins signifi-
cantly reduced total testosterone, free testosterone, cal-
culated free testosterone and bioavailable testosterone 
levels, and that it did so in an age-independent manner.
Statins and total testosterone levels
We merely observed a trend towards lower values of 
total testosterone levels in participants taking statins. 
The difference was not, however, statistically significant 
until the results were adjusted for body mass. When 
this factor was included, use of statins correlated with 
reduced T.
Hall et al. conducted a large epidemiological study 
(Boston Area Community Health [BACH] Survey) in 
1,812 men, 237 of whom were taking statins (simvasta-
hypogonadism (testosterone deficiency syndrome) and 
the associated adverse metabolic phenomena. The ef-
fects of treatment with statins on sex hormone levels 
have been addressed in multiple publications, but the 
results of these studies are equivocal [2–5, 8–12]. 
The aim of our study was to assess the effect of 
treatment with statins on the levels of sex hormones, 
including testosterone, in a male population of Lower 
Silesia (a region of Poland).
Material and methods
Our study was conducted in a group of males partici-
pating in the research project 2P05D07630. The experi-
ment was approved by the Committee for the Ethical 
Conduct of Research Studies. Invitations were sent to 
randomly selected inhabitants of Lower Silesia. A total 
of 237 men (out of 900 men invited) qualified for the 
investigation. Each participant gave written consent 
to the study. 
Medical history including a history of past and 
present illnesses and a smoking history was taken from 
each participant.
Men who were taking medicines that might affect 
serum testosterone levels (androgenic-anabolic steroids, 
GnRH analogues, clomiphene citrate, antiepileptics, 
barbiturates), had a history of endocrine diseases or 
serious general diseases (testicular tumours, ischaemic 
heart disease, heart failure, liver cirrhosis, alcoholism) 
or had other factors that might affect testosterone levels 
(e.g. a vegan diet) were excluded from the study. In the 
present study, to avoid a potential effect of smoking on 
hormone concentrations, we analysed only men who 
did not smoke (n = 189).
The participants were divided into two groups, 
which were uniform in terms of age and body mass: 
a group of 38 men who had been taking statins (Group S; 
age: 58.6 ± 7.6 years) and a group of 151 men who were 
not taking statins (Group NS; age: 57.9 ± 5.6 years). The 
men in Group S had been taking atorvastatin at the dose 
of 20 mg/day or simvastatin at the dose of 20 mg/day 
for at least three months. Most of these men received 
statins for hyperlipidaemia or as part of treatment for 
type 2 diabetes mellitus.
All the men were in a good general condition, and 
43% of them had a college or university degree. The 
most common illnesses declared by the participants 
in the medical history were: hypertension (21%), 
spondylarthritis and peripheral osteoarthritis (19%), 
benign prostatic hyperplasia (5%) and type 2 diabetes 
mellitus (4%).
Blood for testing was collected from an arm vein 
at rest, in the morning, after at least 12 hours’ fast. 
The following were determined: total testosterone (T), 
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tin, pravastatin, lovastatin, fluvastatin and rosuvastatin) 
for a minimum of four weeks, and showed that the 
treated individuals had significantly lower total testos-
terone levels than the untreated ones [2]. 
Two double-blind studies investigating the effect of 
statin treatment on total testosterone levels have been 
published, a study by Dobs et al. and a study by Hyyppa 
et al., both having been conducted in patients with hy-
percholesterolaemia without other co-morbidities [3, 4]. 
A total of 81 patients participated in the study by Dobs 
et al., including 39 men receiving placebo and 41 men 
being treated by simvastatin for 12 weeks at the dose of 
80 mg/day, i.e. four times higher than the dose we used 
in our study. The study showed a significant reduction 
in total testosterone levels in the group receiving statins 
compared to the placebo group [3]. Simvastatin taken in 
a lower dose, 20 mg/day, for 12 weeks also reduced total 
testosterone levels compared to the group of patients 
with hypercholesterolaemia receiving placebo [4]. 
In another study (Rosatto et al.), simvastatin at the 
dose of 80 mg/day also caused a significant reduction 
in total testosterone levels [13]. 
Corona et al. assessed the effect of treatment with 
statins on total testosterone levels in patients evaluated 
for erectile dysfunction [5]. They studied 3,484 men, 244 
of whom were treated with simvastatin or atorvastatin. 
Table I. An average, 95% confidence intervals, and the results of analysis of variance and covariance (body mass as a confounding 
factor) of age, body mass, body mass index and hormone levels in men receiving and not receiving statins (S and NS groups)
Tabela I. Średnia, 95% przedziały ufności i wyniki analizy wariancji i kowariancji (masa ciała jako czynnik zakłócający) 
obejmującej wiek, masę ciała, wskaźnik masy ciała i stężenia hormonów u mężczyzn leczonych i nieleczonych statynami 
(odpowiednio grupa S i NS)
Parameter NS S p1 — analysis of variance
p2 — analysis of covarianceAverage 95% confidence intervals Average 95% confidence intervals
Age (years) 57.43 56.50–58.28 58.57 56.91–60.37 ns
ns
Body mass [kg] 85.03 82.92–87.14 91.44 86.49–95.32 p1 = 0.023
–
BMI [kg/m2] 27.94 27.34–28.55 29.99 28.48–31.50 p1 = 0.024
–
LH [mIU/mL] 5.96 5.36–6.56 5.73 3.99–7.48 ns
ns
FSH [mIU/mL] 8.56 7.53–9.59 9.01 7.70–10.32 ns
ns
E2 [pmol/L] 57.96 54.73–61.19 55.23 49.63–60.83 ns
ns
T [nmol/L] 16.35 15.39–17.31 14.88 13.19–16.57 ns
p2 = 0.008
FT [pmol/L] 39.02 36.87–41.17 32.26 27.98–36.54 p1 = 0.004
p2 = 0.008
cFT [nmol/L] 0.32 0.31–0.34 0.26 0.23–0.29 p1 < 0.001
p2 < 0.001
bioT [nmol/L] 7.56 7.19–7.94 6.10 5.47–6.73 p1 < 0.001
p2 < 0.001
SHBG [nmol/L] 38.16 35.07–41.24 47.20 39.76–54.66 p1 = 0.008
p2 = 0.016
DHEA-S [ng/mL] 462.41 422.41–502.41 391.68 323.33–460.03 ns
ns
T/E2 quotient 0.31 0.29–0.33 0.29 0.25–0.33 ns
p2 = 0,002
FT/E2 quotient 0.74 0.69–0.78 0.61 0.53–0.69 p1 = 0.019
p2 = 0.001
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The study demonstrated that men treated with statins 
had significantly lower total testosterone levels, also 
after adjustments for age and waist circumference.
Not all the studies, however, showed a testosterone-
lowering effects of statins. Results similar to ours were 
obtained by Bohm et al. After examining 15 men and 
seven women, some of whom had been taking pravas-
tatin at the daily dose of 40 mg for three months with 
the others taking placebo, they did not observe any 
differences in total testosterone levels between the 
two groups [9]. 
Also Santini et al., while evaluating total testoster-
one levels before treatment with atorvastatin at the 
dose of 20 mg/day and three months after treatment 
in 16 men, did not observe any significant differences 
in total testosterone levels, even though the levels of 
total cholesterol and LDL-cholesterol decreased and 
reached the upper limits of the reference ranges [10]. 
Many factors may affect total testosterone levels in-
cluding: body mass, BMI, medications, and co-morbidities, 
such as cardiovascular disease [11, 12]. It is therefore be-
lieved that the measurement of total testosterone in the 
older population, especially in patients with testosterone 
deficiency, is inadequate and should be complemented 
by the measurement of free testosterone.
The fact that most of the men we studied had no 
serious co-morbidities could be the reason why we only 
observed a trend towards lower values of total testos-
terone rather than significantly lower levels.
Statins and free testosterone levels
The significantly lower free testosterone level associated 
with statin treatment observed in our study is consistent 
with most of the studies investigating this issue. Both 
large studies (BACH, the project by Corona et al.) and 
smaller projects showed lower free testosterone levels 
in patients treated with statins [2, 5, 13]. 
On the other hand, in the already cited double-
blind study by Dobs et al., although free testosterone 
levels were lower in the group treated with simvastatin 
compared to those in the placebo group, the differences 
were not statistically significant [3]. 
In contrast to the studies cited above, and to our 
study, Santini et al. observed no changes in free tes-
tosterone in subjects treated with statins. The latter 
findings might have been influenced by a small number 
of subjects [10]. 
Statins and bioavailable testosterone levels
Participants in our study who were taking statins had 
significantly lower levels of bioavailable testosterone. 
Our findings are consistent with those of Dobs et al 
[3]. In other studies cited above, this parameter was 
not measured.
Other parameters
In our study, treatment with statins was associated with 
increased levels of SHBG. There are only a few reports 
regarding this issue. In the BACH study, lower values 
of SHBG were observed in men treated with statins [2]. 
On the other hand, data obtained by Dobs et al. and by 
Santini demonstrated that statins did not affect SHBG 
concentration [3, 10]. 
Most of the studies cited above, and our study, did 
not show any effect of statins on the levels of DHEA [9, 
10]. Only the study by Hall et al. demonstrated lower 
levels of DHEA-S in men treated with statins [2]. 
It seems that there are no differences of FSH and 
LH in men receiving or not receiving statins [3, 9, 10]. 
In the study by Corona et al., however, patients treated 
with statins had significantly higher FSH levels. It 
should be noted that the study was conducted in a 
specific group of patients, namely patients with erectile 
dysfunction [5]. 
Kocum et al. investigated the impact of a statin 
dose on sex hormone levels in men. They evaluated 
sex hormone levels after 12 weeks of treatment with 
atorvastatin in two dose ranges: 77 men took doses in 
the range of 40–80 mg/day, and 83 took doses in the 
range of 10–20 mg/day. They observed no significant 
differences in the levels of total testosterone, free tes-
tosterone, SHBG, LH and FSH between the groups [8]. 
A meta-analysis of five studies in men and six stud-
ies in women with polycystic ovary syndrome (PCOS) 
conducted by Schooling et al. confirmed the hypothesis 
that testosterone levels in men decreased as a result of 
treatment with statins [14]. The results of the studies 
included in the meta-analysis were congruent. Only 
the results of the studies conducted in women with 
PCOS were equivocal.
The antiandrogenic effect of statins has been also 
emphasised in a study by Platz et al. that compared 
patients with prostate cancer receiving statins for vari-
ous reasons with patients not receiving statins [15]. The 
antiandrogenic effect of statins contributed to lower 
mortality and lower propensity to metastasis in the 
group of patients treated with these medicines. It was 
shown that the longer the duration of treatment with 
statins, the stronger the effect.
While analysing the effect of the increasingly com-
mon treatment with statins on testosterone levels in 
men, it should be noted that this effect has not yet been 
widely addressed in ageing men [16–18]. This may 
result in overdiagnosis of late-onset hypogonadism 
(LOH) and a too early decision to initiate replacement 
treatment [19–21]. The potential of statins to induce tes-
tosterone deficiency may be of clinical relevance here.
As already mentioned, statins reduce cardiovascular 
mortality, which is unique for lipid-lowering agents. 
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While it is commonly recognised that testosterone de-
ficiency plays an adverse role here, it should be noted 
that men who have undergone castration, or patients 
with Klinefelter syndrome, have lower testosterone 
levels that are associated with lower cardiovascular 
mortality [22, 23]. 
A meta-analysis of studies conducted between 
1970 and 2013 investigating the potential relationship 
between testosterone deficiency and cardiovascular dis-
ease did not unequivocally confirm the negative effects 
of testosterone deficiency, nor did it confirm the benefits 
of testosterone replacement therapy in this respect [24]. 
It is difficult to tell whether lower testosterone levels 
are the cause of cardiovascular disease or the result of 
the routine inclusion of statins in this group of patients 
at diagnosis. The question remains open.
It should also be added that the increased risk of 
type 2 diabetes mellitus associated with statins therapy 
and confirmed by e.g. the study by Sattar et al. may also 
be associated with testosterone level decline. A study by 
Ding et al. showed a relationship between lower serum 
testosterone levels in men and the development of type 
2 diabetes mellitus [25, 26]. 
Conclusions
Our study unequivocally confirms that the use of statins 
is associated with lower levels of: total testosterone, free 
testosterone, calculated free testosterone and bioavail-
able testosterone. This fact carries clinical implications, 
and should be taken into account when diagnosing 
age-related testosterone deficiency.
Further studies are required to elucidate the rela-
tionships between statin therapy and cardiovascular 
mortality, the incidence of type 2 diabetes mellitus, and 
the testosterone-lowering effects of these drugs.
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